Art. -Nr.: HY-N0303

Idebenone

10 Cited Publications

Kundenbewertung

Based on 10 publication(s) in Google Scholar

Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC₅₀=16.65 μM). Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Idebenone quickly crosses the blood-brain barrier.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.84%
CAS. Nr.: 58186-27-9
Formel: C₁₉H₃₀O₅
Molecular Weight:338.44

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Idebenone Chemical Structure

CAS. Nr.: 58186-27-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (10)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Idebenone, a well-appreciated mitochondrial protectant, exhibits protective efficacy against neurotoxicity and can be used for the research of Alzheimer's disease, Huntington's disease. Idebenone (oxidised form) has a dose-dependent inhibitory effect on the enzymatic metabolism of arachidonic acid in astroglial homogenates (IC₅₀=16.65 μM)^[1]. Idebenone, a coenzyme Q10 analog and an antioxidant, induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells^[2]. Idebenone quickly crosses the blood-brain barrier.

Cellular Effect

Cell Line	Type	Value	Description	References
Fibroblast	EC₅₀	592 nM Compound: Idebenone	Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay Cytoprotective activity against BSO-induced human FRDA primary patient fibroblasts compound pretreated 12 hrs prior to BSO-induction measured after 48 hrs by calcein-AM-based cell viability assay	[PMID: 22137789]
Fibroblast	EC₅₀	850 nM Compound: Idebenone	Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability Cytoprotectant activity against L-buthionine-(S,R)-sulfoximine-induced cell death in Friedreich ataxia patient fibroblasts assessed as increase of cell viability	[PMID: 21600768]
Fibroblast	GI₅₀	98 μM Compound: Idebenone	Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay Growth inhibition of human FRDA primary patient fibroblasts after 48 hrs by calcein-AM-based cell viability assay	[PMID: 22137789]
HepG2	EC₅₀	0.94 μM Compound: Idebenone	Suppression of rotenone-induced ATP depletion in human HepG2 cells incubated for 2 hrs by Celltiter-Glo assay Suppression of rotenone-induced ATP depletion in human HepG2 cells incubated for 2 hrs by Celltiter-Glo assay	[PMID: 33180495]
HepG2	IC₅₀	64.5 μM Compound: Idebenone	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-blue assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-blue assay	[PMID: 33180495]
HL-60	IC₅₀	>200 μM Compound: 3	Antiproliferative activity against human mitochondrial gene-knockout HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human mitochondrial gene-knockout HL60 cells after 48 hrs by MTT assay	[PMID: 23432053]
HL-60	IC₅₀	36 μM Compound: 3	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 23432053]
HL-60	IC₅₀	70 μM Compound: 3	Inhibition of tPMET complex in human mitochondrial gene-knockout HL60 cells after 30 mins by WST-1/mPMS reduction assay Inhibition of tPMET complex in human mitochondrial gene-knockout HL60 cells after 30 mins by WST-1/mPMS reduction assay	[PMID: 23432053]
HL-60	IC₅₀	77 μM Compound: 3	Inhibition of tPMET complex in human HL60 cells after 30 mins by WST-1/mPMS reduction assay Inhibition of tPMET complex in human HL60 cells after 30 mins by WST-1/mPMS reduction assay	[PMID: 23432053]
SH-SY5Y	IC₅₀	15.9 μM Compound: Idebenone	Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-blue assay Cytotoxicity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-blue assay	[PMID: 33180495]

In Vitro

Idebenone, a compound with protective efficacy against neurotoxicity both in in vitro and in in vivo models, exists in two different oxidative states: the ubiquinol-derivative (reduced idebenone) and the ubiquinone-derivative (oxidised idebenone)^[1].
Idebenone (oxidised form) preferentially inhibits cyclooxygenase vs. lipoxygenase metabolism (IC₅₀ ratio lipoxygenase/cyclooxygenase: 3.22)^[1].
Idebenone (oxidised form) behaves similarly as indomethacin and piroxicam—two typical anti-inflammatory agents^[1].
Idebenone (oxidised form) inhibits total arachidonic acid metabolism, cyclooxygenase metabolism, lipoxygenase metabolism, lipoxygenase/cyclooxygenase with IC₅₀s of 16.65±3.48, 14.44±2.99, 46.51±7.20, and 3.22 μM^[1].
Idebenone (1-10 μM; for 24-72 h) has no effect on the cell viability of SHSY-5Y cells^[2].
Idebenone (25 μM or higher concentrations; for 24-72 h) shows significant reduction in cell viability of SHSY-5Y cells^[2].
Idebenone (30 μM) induces up-regulation of BAX expression and the caspase-3 activity^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:

The human dopaminergic neuroblastma cell line, SHSY-5Y cells
Concentration:

1, 3, 10, 15, 25, 30, and 90 μM
Incubation Time:

24, 48, and 72 hours
Result:

Had no apparent detrimental effects on cell viability as indicated by the absence of trypan blue-positive staining in the cells at concentrations of 1, 3, 10 μM.
Exhibited some degree of trypan blue-positive staining at 15 μM. Showed extensive trypan blue-positive staining at 25 μM and 30 μM.

RT-PCR^[2]

Cell Line:

SHSY-5Y cells
Concentration:

10 μM, 30 μM
Incubation Time:

72 hours
Result:

The total RNA of BAX from SHSY-5Y cells exposed to 10 μM was not different from that of the untreated control cells.
The BAX expression in SHSY-5Y cells exposed to 30 μM was significantly up-regulated when compared with the untreated control cells and cells exposed to 10 μM.

In Vivo

Idebenone (oxidised form) is a compound with protective efficacy against cerebrovascular disorders in vivo, including cerebral ischemia and hypertension-induced vascular lesions^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 58186-27-9
Appearance Solid
Molecular Weight 338.44
Formel C₁₉H₃₀O₅
Color Yellow to orange
SMILES

O=C1C(CCCCCCCCCCO)=C(C)C(C(OC)=C1OC)=O
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (10)

All RT-PCRHistological Imaging/StainingIn Vivo Efficacy StudyWB

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Fe-S Protein FDX1 Triggers Tumor-Intrinsic Innate Immunity via Mitochondrial Nucleic Acids Release to Orchestrate Ferroptosis in CCRCC. [Abstract]

2025 Nov 7:e18323. PMID: 41199656

Idebenone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 7:e18323. [Abstract]

Immunoblots of ferroptosis markers in FDX1-overexpressing cells treated with Fer-1 (10 µM), Idebenone (IDE, 50 µM), DFO (100 µM), or 7-DHC (50 µM) for 24 h; β-tubulin-normalized expression shown.
J Neuroinflammation

Pharmacological inhibition of the cGAS-STING pathway suppresses microglia pyroptosis in sepsis-associated encephalopathy. [Abstract]

2025 Jul 9;22(1):176. PMID: 40634978

Idebenone purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Jul 9;22(1):176. [Abstract]

Idebenone (10 mg/kg; i.p.; single dose) significantly inhibited the upregulation of mRNA levels of STING, IFN-α, IFN-β, IL-1β, GSDMD, NLRP3, and Caspase-1 in the hippocampus of mice subjected to cecal ligation and puncture (CLP).

Idebenone purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Jul 9;22(1):176. [Abstract]

Idebenone (10 mg/kg; i.p.; single dose) alleviated cecal ligation and puncture (CLP)-induced neuronal damage, restored the integrity of cellular structure, and reduced pyknotic nuclei.

Idebenone purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2025 Jul 9;22(1):176. [Abstract]

Idebenone (10 mg/kg; i.p.; single dose) significantly improved the 5-day survival rate of cecal ligation and puncture (CLP)-induced septic mice compared to untreated controls.
Phytomedicine

Jiawei Xionggui Decoction promotes meningeal lymphatic vessels clearance of β-amyloid by inhibiting arachidonic acid pathway. [Abstract]

2024 Sep 12:135:156041. PMID: 39299091

Idebenone purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2024 Sep 12:135:156041. [Abstract]

Idebenone (Ideb, 15 µM; 24.5 h) significantly inhibited the enhanced expression of COX-2 in C8-D1A cells induced by Aβ_23-35 (100 µM; 24 h).
Mater Design

2024 Apr 25:112972
Free Radic Biol Med

Ferroptosis suppressor protein 1 regulated oligodendrocytes ferroptosis rescued by idebenone in spinal cord injury. [Abstract]

2025 Feb 1:227:129-142. PMID: 39626861
Eur J Pharmacol

Idebenone attenuates ferroptosis by inhibiting excessive autophagy via the ROS-AMPK-mTOR pathway to preserve cardiac function after myocardial infarction. [Abstract]

2023 Mar 15:943:175569. PMID: 36740037
Neuropsychiatr Dis Treat

Therapeutic Effect of Idebenone on Rats with Vascular Dementia via the MicroRNA-216a/RSK2/NF-κB Axis. [Abstract]

2021 Feb 17:17:533-543. PMID: 33628024
Res Sq

2026 Mar 4.
Heliyon

Synergistic delivery of hADSC-Exos and antioxidants has inhibitory effects on UVB-induced skin photoaging. [Abstract]

2024 Jul 9;10(15):e34321. PMID: 39144947
Oncotarget

Synergistic neuroprotective effect of rasagiline and idebenone against retinal ischemia-reperfusion injury via the Lin28-let-7-Dicer pathway. [Abstract]

2018 Jan 30;9(15):12137-12153. PMID: 29552298

Idebenone purchased from MedChemExpress. Usage Cited in: Oncotarget. 2018 Jan 30;9(15):12137-12153. [Abstract]

Retinal protection of Rasagiline combined with Idebenone against retinal ischemia-reperfusion (RIR) injury. Western blot analysis for the expression level of brain-derived neurotrophic factor (BDNF) in the whole IR-injured retinas.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (295.47 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9547 mL

14.7737 mL

29.5473 mL

5 mM

0.5909 mL

2.9547 mL

5.9095 mL

10 mM

0.2955 mL

1.4774 mL

2.9547 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.39 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. G Civenni, et al. Inhibitory effect of the neuroprotective agent idebenone on arachidonic acid metabolism in astrocytes.Eur J Pharmacol. 1999 Apr 9;370(2):161-7. [Content Brief]

[2]. Kwok-Keung Tai, et al. Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Neurotox Res. 2011 Nov;20(4):321-8. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9547 mL	14.7737 mL	29.5473 mL	73.8683 mL
	5 mM	0.5909 mL	2.9547 mL	5.9095 mL	14.7737 mL
	10 mM	0.2955 mL	1.4774 mL	2.9547 mL	7.3868 mL
	15 mM	0.1970 mL	0.9849 mL	1.9698 mL	4.9246 mL
	20 mM	0.1477 mL	0.7387 mL	1.4774 mL	3.6934 mL
	25 mM	0.1182 mL	0.5909 mL	1.1819 mL	2.9547 mL
	30 mM	0.0985 mL	0.4925 mL	0.9849 mL	2.4623 mL
	40 mM	0.0739 mL	0.3693 mL	0.7387 mL	1.8467 mL
	50 mM	0.0591 mL	0.2955 mL	0.5909 mL	1.4774 mL
	60 mM	0.0492 mL	0.2462 mL	0.4925 mL	1.2311 mL
	80 mM	0.0369 mL	0.1847 mL	0.3693 mL	0.9234 mL
	100 mM	0.0295 mL	0.1477 mL	0.2955 mL	0.7387 mL

Keywords

Idebenone

10 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Idebenone

Apoptosis Compound Library

Metabolism/Protease Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Covalent Screening Library

Antioxidant Compound Library

NMPA-Approved Drug Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Mitochondria-Targeted Compound Library

Glucose Metabolism Compound Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Cuproptosis Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Mitochondrial Toxicity Compound Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Anti-Fibrosis Compound Library

Vitamin Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Drug Fragment Library

Publications Citing Use of MedChemExpress (MCE) Idebenone

Biologische Aktivität

Chemical Information

Publications (10)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Idebenone Related Classifications

HY-N0303 Related Classifications